Opinion|Videos|August 8, 2024
Interpreting and Communicating ctDNA Results
The panel examines challenges in interpreting circulating tumor DNA results and their impact on clinical decision-making processes.
Advertisement
Episodes in this series
- How do you factor ctDNA into treatment selection and management?
- How do you integrate ctDNA with radiographic or pathologic correlates?
- Are there challenges associated with the interpretation of ctDNA to inform your clinical decision-making?
- What do we know about sensitivity of ctDNA with different sites of metastatic disease?
- Navigating positive results
- Navigating false negatives
- How do you describe these test results to patients?
- Do you have any practical insights to share for interpretating and presenting results?
Advertisement
Related to this article
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer
2
RYZ101 Improves Progression-Free Survival in Previously Treated GEP-NETs
3
Why CAR T-Cell Therapy Before Bispecifics May Be the Ideal Multiple Myeloma Sequence
4
Teclistamab Vs Talquetamab After Relapse on CAR T-Cell Therapy in Multiple Myeloma
5